Seres Therapeutics Inc MCRB
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2015-06-26 |
| Shares Out. | 9,680,000 |
| Website | serestherapeutics.com/ ↗ |
| Phone | 13026587581 |
| Employees | 66 |
| Revenue | $736,000 |
| Gross Profit | $736,000 |
| Net Income | $4.6M |
| Free Cash Flow | -$51.3M |
| Total Assets | $101.6M |
| Total Liabilities | $67.1M |
| Equity | $34.5M |
About Seres Therapeutics Inc
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.
Seres Therapeutics Inc is a publicly traded company under the ticker symbol MCRB on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
8 analysts (2026-09-01)